Condition: Acute Myeloid Leukemia · Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
The current standard of care treatment for adult patients with acute myeloid leukemia (AML) consists of chemotherapy and, if indicated, donor stem cell transplantation. Bleximenib blocks the interaction between a protein called menin and another protein called KMT2A in the leukemia cells. When this interaction is disrupted in AML with mutations in the NPM1 or KMT2A gene, bleximenib can cause leukemia cells to die. The main objective is to assess if treatment with bleximenib, when added to chemotherapy treatment will improve treatment outcome in adult participants with newly diagnosed AML who present with mutations in the NPM1 or KMT2A genes. This is a randomized, double-blind, placebo-controlled, phase 3 clinical trial. All of the participants will receive standard chemotherapy treatment, combined with either bleximenib or a placebo. A placebo is a substance that looks like the study medicine but has no active ingredients (e.g., a sugar pill). In a double blind trial neither the participant nor the doctor know if placebo or active study drug is given. After the end of the protocol treatment there will be an observational follow-up of 4 years from the time of inclusion of the last patient. The results of the different treatment groups will be compared. 875 previously untreated patients with AML with a specific change in the DNA of the leukemia cells (a KMT2A rearrangement or a NPM1 mutation) will be included. Participants must be 18 years or older and considered eligible …
This description comes directly from the study's public registry record.
M.H.G.P. Raaijmakers · 010 7033740 · m.h.g.raaijmakers@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| US-San Francisco CA-UCSF | San Francisco, California, United States | Recruiting |
| US-Atlanta GA-EMORY | Atlanta, Georgia, United States | Recruiting |
| US-Kansas City KS-KUMC | Kansas City, Kansas, United States | Recruiting |
| US-Baltimore MD-UMGCCC | Baltimore, Maryland, United States | Recruiting |
| US-St Louis MO-WASHU | St Louis, Missouri, United States | Recruiting |
| US-Cincinnati OH-CINCY | Cincinnati, Ohio, United States | Recruiting |
| AU-Adelaide-FLINDERS | Adelaide, Australia | Recruiting |
| AU-Adelaide-RAH | Adelaide, Australia | Recruiting |
| AU-Birtinya-SUNSHINECOAST | Birtinya, Australia | Recruiting |
| AU-Brisbane-PAH | Brisbane, Australia | Recruiting |
| AU-Camperdown-RPA | Camperdown, Australia | Recruiting |
| AU-Melbourne-AUSTIN | Melbourne, Australia | Recruiting |
+ 31 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223814